Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.57 |
| ▸ | LCK | P06239 | 10/20 | 0.56 |
| ▸ | JAK3 | P52333 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316402 | 0.91 | BTK (0.59) | BTKLCKJAK3 | |
| SCHEMBL3316025 | 0.88 | BTK (0.56) | BTKLCKJAK3 | |
| SCHEMBL3316330 | 0.87 | BTK (0.59) | BTKLCKJAK3 | |
| SCHEMBL3316974 | 0.84 | BTK (0.48) | BTKLCKJAK3 | |
| SCHEMBL3316693 | 0.83 | BTK (0.58) | BTKLCKJAK3 | |
| SCHEMBL3318387 | 0.82 | BTK (0.60) | BTKLCKJAK3 | |
| SCHEMBL3409941 | 0.80 | BTK (0.59) | BTKLCKJAK3 | |
| SCHEMBL3316306 | 0.80 | BTK (0.59) | BTKLCKJAK3 | |
| SCHEMBL3313920 | 0.80 | BTK (0.59) | BTKLCKJAK3 | |
| SCHEMBL3797736 | 0.80 | BTK (0.57) | BTKLCKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125819-B1 | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases | BRISTOL MYERS SQUIBB CO (US) | 2014-10-22 | — | — | EP | disclosed |
| US-8188272-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100105676-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-29 | — | — | US | disclosed |
| EP-2125819-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE, ALLERGIC, AUTOIMMUNE OR INFLAMMATORY DISEASES | Bristol-Myers Squibb Company (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008116064-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE, ALLERGIC, AUTOIMMUNE OR INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105676-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BTK, LYN, ABL1 | BTK 1/4885LCK 5/4885JAK3 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.